Loading
A phase 1/2 trial of ACR-2316 run by Acrivon Therapeutics, now recruiting.
Study of ACR-2316 in Specific Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06667141 by Acrivon Therapeutics, with 100 participants planned, started 2024-10-08. Conditions recorded: Specific Advanced Solid Tumors. Interventions recorded: ACR-2316.
Shares Acrivon Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/